Résumé : Myeloid Human immunodeficiency virus type 1 (HIV-1) reservoirs such as brain microglia andurethral macrophages are increasingly recognized as physiologically relevant, yet the molecularmechanisms of HIV-1 gene expression in these cells remain poorly understood. The intrageniccis-regulatory region (IRR) located in the pol gene enhances transcription from the 5’LTR andcontains multiple transcription factor binding sites. Here, we focused on the myeloid-specifictranscription factor PU.1, a pioneer factor that opens heterochromatin at enhancers, andcharacterized its role in IRR-mediated regulation.We demonstrated in vivo recruitment of PU.1 to the intragenic enhancer in infected myeloid celllines. In vitro, we mapped PU.1 binding to distinct intragenic PU-boxes and identified mutationsabolishing PU.1 binding without affecting the pol coding sequence. Using these mutated viralparticles in single-round infection experiments, we showed that PU-boxes are critical for the IRRenhancer activity, epigenetic profile, recruitment of enhancer-associated cofactors, andchromatin accessibility.The importance of intragenic PU.1 sites for HIV-1 replication was further confirmed in primarymonocyte-derived macrophages. RNA interference experiments in myeloid cell lines validatedthe role of PU.1 in sustaining viral gene expression. As a proof-of-concept for therapeuticapplications, we demonstrated that a specific inhibitor interfering with PU.1 binding impairs HIV1 expression, suggesting a novel strategy to target myeloid reservoirs.The HIV-1 intragenic enhancer thus emerges as a key regulatory element in viral transcription.By contributing to a finely tuned control of HIV-1 expression across diverse chromatin and cellularenvironments, the IRR highlights new avenues for cure strategies targeting the heterogeneousreservoirs that sustain viral persistence.